The stock price of Terns Pharmaceuticals Inc (NASDAQ: TERN) has plunged by -4.13 when compared to previous closing price of 6.05, but the company has seen a 9.64% gain in its stock price over the last five trading sessions. Market Watch reported 2024-03-28 that The stock of small-cap Terns Pharmaceuticals Inc. rose 6% on Thursday, amid bullish analyst comment on the company’s pipeline, which includes an oral treatment for obesity that one bank believes could send the stock sharply higher.
Is It Worth Investing in Terns Pharmaceuticals Inc (NASDAQ: TERN) Right Now?
TERN has 36-month beta value of -0.45. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TERN is 41.14M, and currently, short sellers hold a 10.69% ratio of that float. The average trading volume of TERN on May 09, 2024 was 941.50K shares.
TERN’s Market Performance
TERN’s stock has seen a 9.64% increase for the week, with a 10.48% rise in the past month and a -7.50% fall in the past quarter. The volatility ratio for the week is 6.69%, and the volatility levels for the past 30 days are at 6.71% for Terns Pharmaceuticals Inc The simple moving average for the last 20 days is 14.68% for TERN stock, with a simple moving average of 0.19% for the last 200 days.
Analysts’ Opinion of TERN
Many brokerage firms have already submitted their reports for TERN stocks, with Mizuho repeating the rating for TERN by listing it as a “Buy.” The predicted price for TERN in the upcoming period, according to Mizuho is $16 based on the research report published on June 22, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see TERN reach a price target of $18. The rating they have provided for TERN stocks is “Buy” according to the report published on June 07th, 2023.
ROTH MKM gave a rating of “Buy” to TERN, setting the target price at $23 in the report published on May 31st of the previous year.
TERN Trading at -3.86% from the 50-Day Moving Average
After a stumble in the market that brought TERN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.23% of loss for the given period.
Volatility was left at 6.71%, however, over the last 30 days, the volatility rate increased by 6.69%, as shares surge +9.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.35% lower at present.
During the last 5 trading sessions, TERN rose by +8.52%, which changed the moving average for the period of 200-days by -16.56% in comparison to the 20-day moving average, which settled at $5.08. In addition, Terns Pharmaceuticals Inc saw -10.63% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TERN starting from Vivo Opportunity, LLC, who sale 138,066 shares at the price of $6.20 back on Apr 03 ’24. After this action, Vivo Opportunity, LLC now owns 268,573 shares of Terns Pharmaceuticals Inc, valued at $856,009 using the latest closing price.
Vivo Opportunity, LLC, the 10% Owner of Terns Pharmaceuticals Inc, sale 101,480 shares at $6.65 during a trade that took place back on Apr 02 ’24, which means that Vivo Opportunity, LLC is holding 272,722 shares at $674,842 based on the most recent closing price.
Stock Fundamentals for TERN
The total capital return value is set at -0.4. Equity return is now at value -33.89, with -32.48 for asset returns.
Based on Terns Pharmaceuticals Inc (TERN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -111.76. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 39.92.
Currently, EBITDA for the company is -101.68 million with net debt to EBITDA at 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.39.
Conclusion
To put it simply, Terns Pharmaceuticals Inc (TERN) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
